Systemic immune-inflammatory index predict short-term outcome in recurrent/metastatic and locally advanced cervical cancer patients treated with PD-1 inhibitor
Abstract This study aims to assess the predictive value of certain markers of inflammation in patients with locally advanced or recurrent/metastatic cervical cancer who are undergoing treatment with anti-programmed death 1 (PD-1) therapy. A total of 105 patients with cervical cancer, who received tr...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-12-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-82976-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850102847867191296 |
|---|---|
| author | Qingqing Chen Baoqian Zhai Jingjing Li Hui Wang Zhengcao Liu Runjun Shi Haohao Wu Yingying Xu Shengjun Ji |
| author_facet | Qingqing Chen Baoqian Zhai Jingjing Li Hui Wang Zhengcao Liu Runjun Shi Haohao Wu Yingying Xu Shengjun Ji |
| author_sort | Qingqing Chen |
| collection | DOAJ |
| description | Abstract This study aims to assess the predictive value of certain markers of inflammation in patients with locally advanced or recurrent/metastatic cervical cancer who are undergoing treatment with anti-programmed death 1 (PD-1) therapy. A total of 105 patients with cervical cancer, who received treatment involving immunocheckpoint inhibitors (ICIs), were included in this retrospective study. We collected information on various peripheral blood indices, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), and prognostic nutritional index (PNI). To determine the appropriate cutoff values for these inflammatory markers, we performed receiver operating characteristic curve (ROC) analysis. Progression-free survival (PFS) was estimated using the Kaplan-Meier method, and we conducted both univariate and multivariate Cox regression analyses to evaluate the prognostic value of these markers. Out of the 105 patients who received ICI treatment, the median progression-free survival (mPFS) was 19.0 months. We obtained the patients’ clinical characteristics, such as age, pathological type, therapy regimen, Figo stage, NLR, PLR, LMR, SII, and PNI from their medical records. The optimal cutoff values for NLR, PLR, LMR, SII, and PNI were determined as 3.76, 218.1, 3.34, 1147.7, 43.75, respectively. In the univariate analysis, age, pathological type, therapy regimen, Figo stage, and LMR were not found to be associated with PFS. However, high NLR(P=0.001), high PLR(P<0.001), high SII(P<0.001), and low PNI (P=0.003)were all associated with shorter PFS. Multivariate analysis indicated that SII (P=0.017) was an independent risk factor for PFS. This study highlights the potential use of SII as a predictor of progression-free survival in cervical cancer patients undergoing immunotherapy. |
| format | Article |
| id | doaj-art-8ca73f8c596441f39f9da70282d8a254 |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-8ca73f8c596441f39f9da70282d8a2542025-08-20T02:39:40ZengNature PortfolioScientific Reports2045-23222024-12-011411910.1038/s41598-024-82976-6Systemic immune-inflammatory index predict short-term outcome in recurrent/metastatic and locally advanced cervical cancer patients treated with PD-1 inhibitorQingqing Chen0Baoqian Zhai1Jingjing Li2Hui Wang3Zhengcao Liu4Runjun Shi5Haohao Wu6Yingying Xu7Shengjun Ji8Department of Radiotherapy & Oncology, The Affiliated Suzhou Hospital of Nanjing Medical UniversityDepartment of Radiotherapy Oncology, Yancheng City No.1 People’s Hospital, The Fourth Affiliated Hospital of Nantong UniversityDepartment of Radiotherapy & Oncology, The Affiliated Suzhou Hospital of Nanjing Medical UniversityDepartment of Radiotherapy Oncology, Yancheng City No.1 People’s Hospital, The Fourth Affiliated Hospital of Nantong UniversityDepartment of Radiotherapy & Oncology, The Affiliated Suzhou Hospital of Nanjing Medical UniversityDepartment of Radiotherapy & Oncology, The Affiliated Suzhou Hospital of Nanjing Medical UniversityDepartment of Radiotherapy Oncology, Yancheng City No.1 People’s Hospital, The Fourth Affiliated Hospital of Nantong UniversityDepartment of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow UniversityDepartment of Radiotherapy & Oncology, The Affiliated Suzhou Hospital of Nanjing Medical UniversityAbstract This study aims to assess the predictive value of certain markers of inflammation in patients with locally advanced or recurrent/metastatic cervical cancer who are undergoing treatment with anti-programmed death 1 (PD-1) therapy. A total of 105 patients with cervical cancer, who received treatment involving immunocheckpoint inhibitors (ICIs), were included in this retrospective study. We collected information on various peripheral blood indices, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), and prognostic nutritional index (PNI). To determine the appropriate cutoff values for these inflammatory markers, we performed receiver operating characteristic curve (ROC) analysis. Progression-free survival (PFS) was estimated using the Kaplan-Meier method, and we conducted both univariate and multivariate Cox regression analyses to evaluate the prognostic value of these markers. Out of the 105 patients who received ICI treatment, the median progression-free survival (mPFS) was 19.0 months. We obtained the patients’ clinical characteristics, such as age, pathological type, therapy regimen, Figo stage, NLR, PLR, LMR, SII, and PNI from their medical records. The optimal cutoff values for NLR, PLR, LMR, SII, and PNI were determined as 3.76, 218.1, 3.34, 1147.7, 43.75, respectively. In the univariate analysis, age, pathological type, therapy regimen, Figo stage, and LMR were not found to be associated with PFS. However, high NLR(P=0.001), high PLR(P<0.001), high SII(P<0.001), and low PNI (P=0.003)were all associated with shorter PFS. Multivariate analysis indicated that SII (P=0.017) was an independent risk factor for PFS. This study highlights the potential use of SII as a predictor of progression-free survival in cervical cancer patients undergoing immunotherapy.https://doi.org/10.1038/s41598-024-82976-6Cervical cancerImmunotherapyInflammatory markersPrognosis |
| spellingShingle | Qingqing Chen Baoqian Zhai Jingjing Li Hui Wang Zhengcao Liu Runjun Shi Haohao Wu Yingying Xu Shengjun Ji Systemic immune-inflammatory index predict short-term outcome in recurrent/metastatic and locally advanced cervical cancer patients treated with PD-1 inhibitor Scientific Reports Cervical cancer Immunotherapy Inflammatory markers Prognosis |
| title | Systemic immune-inflammatory index predict short-term outcome in recurrent/metastatic and locally advanced cervical cancer patients treated with PD-1 inhibitor |
| title_full | Systemic immune-inflammatory index predict short-term outcome in recurrent/metastatic and locally advanced cervical cancer patients treated with PD-1 inhibitor |
| title_fullStr | Systemic immune-inflammatory index predict short-term outcome in recurrent/metastatic and locally advanced cervical cancer patients treated with PD-1 inhibitor |
| title_full_unstemmed | Systemic immune-inflammatory index predict short-term outcome in recurrent/metastatic and locally advanced cervical cancer patients treated with PD-1 inhibitor |
| title_short | Systemic immune-inflammatory index predict short-term outcome in recurrent/metastatic and locally advanced cervical cancer patients treated with PD-1 inhibitor |
| title_sort | systemic immune inflammatory index predict short term outcome in recurrent metastatic and locally advanced cervical cancer patients treated with pd 1 inhibitor |
| topic | Cervical cancer Immunotherapy Inflammatory markers Prognosis |
| url | https://doi.org/10.1038/s41598-024-82976-6 |
| work_keys_str_mv | AT qingqingchen systemicimmuneinflammatoryindexpredictshorttermoutcomeinrecurrentmetastaticandlocallyadvancedcervicalcancerpatientstreatedwithpd1inhibitor AT baoqianzhai systemicimmuneinflammatoryindexpredictshorttermoutcomeinrecurrentmetastaticandlocallyadvancedcervicalcancerpatientstreatedwithpd1inhibitor AT jingjingli systemicimmuneinflammatoryindexpredictshorttermoutcomeinrecurrentmetastaticandlocallyadvancedcervicalcancerpatientstreatedwithpd1inhibitor AT huiwang systemicimmuneinflammatoryindexpredictshorttermoutcomeinrecurrentmetastaticandlocallyadvancedcervicalcancerpatientstreatedwithpd1inhibitor AT zhengcaoliu systemicimmuneinflammatoryindexpredictshorttermoutcomeinrecurrentmetastaticandlocallyadvancedcervicalcancerpatientstreatedwithpd1inhibitor AT runjunshi systemicimmuneinflammatoryindexpredictshorttermoutcomeinrecurrentmetastaticandlocallyadvancedcervicalcancerpatientstreatedwithpd1inhibitor AT haohaowu systemicimmuneinflammatoryindexpredictshorttermoutcomeinrecurrentmetastaticandlocallyadvancedcervicalcancerpatientstreatedwithpd1inhibitor AT yingyingxu systemicimmuneinflammatoryindexpredictshorttermoutcomeinrecurrentmetastaticandlocallyadvancedcervicalcancerpatientstreatedwithpd1inhibitor AT shengjunji systemicimmuneinflammatoryindexpredictshorttermoutcomeinrecurrentmetastaticandlocallyadvancedcervicalcancerpatientstreatedwithpd1inhibitor |